VAREX IMAGING CORP (VREX)
Health Care · Medical imaging components and X-ray equipment manufacturing · NASDAQ
Varex Imaging is a leading global supplier of mission-critical X-ray imaging components used in medical, security, and industrial diagnostic applications.
What VAREX IMAGING CORP does
Varex Imaging Corporation is a leading designer and manufacturer of X-ray imaging components, including X-ray tubes, flat panel and photon counting detectors, linear accelerators, image software processing solutions, and stand-alone X-ray systems. The company supplies global OEMs that incorporate these components into medical diagnostic imaging, security inspection, industrial quality inspection, and industrial manufacturing applications.
Themes: Medical diagnostic imaging, Security inspection systems, Industrial quality inspection, X-ray components and imaging, Medical device manufacturing
Fundamentals
- Price$18.51 as of 2026-08-21 close
- Market cap$779M as of 2026-08-21
- 1-year return+63.2% 2025-08-21 close $11.34 → 2026-08-21 close $18.51
- P/En/a negative earnings
- Net margin-9.6% as of 2026-08-24
- Gross margin+33.5% as of 2026-08-24
- ROE-17.6% as of 2026-08-24
- Debt / equity0.74 as of 2026-08-24
- Revenue growth (YoY)+3.6% as of 2026-08-24
- Revenue CAGR (3y)-0.6% SEC XBRL
- Beta0.98 as of 2026-08-24
- Last reported earnings2026-08-10 SEC EDGAR Form 8-K (Item 2.02)
How VREX compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginbottom 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How VAREX IMAGING CORP looks technically
VAREX IMAGING CORP (VREX) is trading 54.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 3 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 51, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 90, in overbought territory (above 70). It made a new 20-day high about 9 trading days ago. It is 0.6% below its 52-week high (its highest price of the past year).
Trend
9
| Distance from the 200-day | it is trading 54.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +54.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $12.40 | $12.40 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $12.02 | $12.02 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 11.23. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible upward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 3 trading days ago — a "golden cross", a bullish long-term signal | 3 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 54.0% above | +54.0% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 51, with buyers in control | 51.3 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 90, in overbought territory (above 70) | 90.4 |
|---|---|---|
| Position in its 14-day range | it is trading right at the top of its 14-day range ($11.90 to $18.63) — its "stochastic" reading is 98 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 98.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 21 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $18.63 | $18.63 |
|---|---|---|
| From the 52-week high | it is 0.6% below its 52-week high (its highest price of the past year) | -0.6% |
| Above the 52-week low | it is 103.6% above its 52-week low (its lowest price of the past year) | +103.6% |
| Below the 52-week high | it is at or near its highest point of the past year | 0.6% |
| Since a 20-day breakout | it made a new 20-day high about 9 trading days ago | 9 sessions |
| Since a 55-day breakout | it made a new 55-day high about 9 trading days ago | 9 sessions |
| All-time high | its highest closing price on record is $43.76 (set on 2018-01-29) | $43.76 |
| Given back of the 52-week move | over the past year its closes ranged ($9.32 to $18.58), and it has given back essentially none of its rise from last year’s low — 1% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $12.56 to $12.86. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.8% |
| From the all-time high | it is 57.7% below its all-time high | -57.7% |
| Nearest price level | it is trading 17.0% above a support level at $15.36 — a price it turned at twice since 2024-12-27, most recently on 2025-02-06. Since 2024-08-21 it has 17 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -17.0% |
| All-time low | its lowest closing price on record is $6.76 (set on 2025-05-09) | $6.76 |
| Above the all-time low | it is 173.8% above its all-time low | +173.8% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 94% of the past ~6 months) | 94th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4903 between its high and its low — about 2.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4903 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $8.20 and $21.95 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $8.20 – $15.08 – $21.95 |
| Typical daily range (% of price) | its price moves about 2.7% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.6% |
| Stretch from the 200-day average | it is trading 13.3 daily ranges above its 200-day average price (54.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 13.3 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.90× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 5.1% since the prior reading | +5.1% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 at essentially the same price it closed at the session before — no meaningful overnight gap | 0.0% |
|---|---|---|
| Open gap | it gapped 48.2% above the previous close 9 sessions ago and has not traded back through the level it left behind at 12.41 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +48.2% |
| Gap filled | a 2.0% gap up opened on 2026-08-04 has been "filled" 13 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 13 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +0.27% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 70.3 percentage points (the stock gained 72.7% while the market gained 2.3%) | +70.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 79.6 percentage points (the stock gained 82.7% while the market gained 3.1%) | +79.6% |
| vs market, 6 months | over the past 6 months this stock beat the market by 25.1 percentage points (the stock gained 36.2% while the market gained 11.1%) | +25.1% |
| vs market, 12 months | over the past 12 months this stock beat the market by 42.7 percentage points (the stock gained 63.2% while the market gained 20.5%) | +42.8% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: its RSI momentum gauge is overbought (a stretched reading), near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 69% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thin, spanning 1.7% of the share price, which is taken to mean a barrier that gives way easily. | +69.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 35% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $13.75 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +34.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is sitting right on the average price paid since it last reported on 2026-08-10 (its 10-Q), so the typical buyer over that stretch is roughly break-even. That average is $18.48 — a volume-weighted average of daily closes over 10 sessions, not a true tick-by-tick VWAP. | +0.2% |
Price levels it has turned at before
VREX last closed at $18.51 on 2026-08-21. Since 2024-08-21 it has turned at 17 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $15.36 | Support | 17.0% below the last close | turned there twice · 2024-12-27 to 2025-02-06 |
| $14.47 | Support | 21.8% below the last close | turned there four times · 2025-01-27 to 2026-02-10 |
| $13.45 | Support | 27.4% below the last close | turned there twice · 2024-11-14 to 2025-02-26 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $11.23.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $14.32 and $16.60 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close above $18.63.
This reading has stood for 4 trading days, since 2026-08-18.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · Overbought (14-day RSI above 70) · Near the 52-week high · in a strong, established uptrend (ADX) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (3.00 mean, 1=Strong Buy…5=Strong Sell) — 4 analysts
- Mean price target$18.93 range $18.90 – $19.00; median $18.90
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for VREX
- Consensus EPS estimate$0.294 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Concentrated customer base: reduction in or loss of business from one or more limited OEM customers could materially impact revenues.","Tariffs, trade wars, and international operations: changes in import/export regulatory regimes and geopolitical instability could disrupt manufacturing and supply chains.","Supply chain and cost pressures: inflation, supply chain disruptions, and reliance on limited suppliers for key components could increase costs and delay deliveries."]
What changed in the latest 10-Q
AI-assisted comparison of VREX's 10-Q filed 2026-05-07 against the prior one filed 2026-02-10.
Management's Discussion & Analysis (MD&A)
- Added:
- New section 'Debt Refinance' describing $490 million secured credit facility, $350 million term loan, $100 million revolving credit facility, $40 million delayed draw term loan, redemption of $368 million 7.875% Senior Secured Notes due 2027, termination of prior $155 million facility, interest rate terms, and expected $7+ million annual interest savings (filed 2026-05-07)
- New section 'Current Economic and Trade Environment' with opening language about dynamic and unpredictable environment (filed 2026-05-07)
- Removed:
- Section titled 'Impact of Current Economic and Trade Environment' discussing tariff effects, supply chain challenges, geopolitical tensions, delayed purchasing decisions, sustained US government shutdown risk, and specific 2025 tariff policy changes (filed 2026-02-10)
- Reworded:
- Employee count changed from 'approximately 2,400 full-time equivalent employees' to 'approximately 2,450 full-time equivalent employees' (filed 2026-05-07)
- Risk factor list reordered: moved 'challenges in accurately predicting product demand and delivery schedules' and 'loss of business to, and an inability to effectively compete with, competitors' earlier in sequence (filed 2026-05-07)
- Supply chain risk factor language simplified from 'supply chain disruptions resulting in delayed product delivery, and increased costs as a result of reliance on a limited number of suppliers for certain key components' to 'inflation and supply chain disruptions resulting in increased costs and delayed product delivery' (filed 2026-05-07)
- Debt financing risk factor shortened from 'limitations imposed by operating and financial restrictions of our debt financing agreements that could harm our long-term interests, limit our ability to make payments on our debt obligations, and impact our ability to maintain sufficient liquidity and/or to refinance our debt obligations' to 'limitations imposed by operating and financial restrictions of our debt financing' (filed 2026-05-07)
- Notes:
- The newer filing's 'Current Economic and Trade Environment' section appears incomplete/truncated in the source text provided, limiting full assessment of changes in that section
Risk Factors
- Added:
- Added reference to 'the United States and Israel conflict with Iran' in geopolitical tensions section (newer filing 2026-05-07)
- Added language: 'The current conflict in Iran, for example, has and may continue to cause increases in cost of goods and raw materials, transportation, and other costs' (newer filing 2026-05-07)
- Extended disclosure to 'first six months of fiscal year 2026' instead of 'first quarter fiscal year 2026' (newer filing 2026-05-07)
- Added text: 'Tensions and conflicts between countries, including those discussed in this risk factor, have in the past, are currently, and may in the future continue to, adversely impact our costs, margins, supply chain, and ability to timely deliver products to our customers, and these risks could continue to harm our business, financial condition, and results of operations' (newer filing 2026-05-07)
- Removed:
- Removed phrase 'as well as local conflicts' and replaced with expanded description (older filing 2026-02-10)
- Removed reference to 'In the past, such actions both in China and Russia, have caused, are causing, and could in the future cause' (older filing 2026-02-10)
- Removed concluding phrase 'and materially harm our business, financial condition, and results of operations' from geopolitical section (older filing 2026-02-10)
- Reworded:
- Changed 'in the first quarter fiscal year 2026' to 'in the first half of fiscal year 2026' (newer filing 2026-05-07)
- Changed 'the tariffs are expected' to 'tariffs are expected' (newer filing 2026-05-07)
- Changed 'Increasing tensions between countries, such as China and Taiwan, as well as local conflicts including the Ukraine-Russia war and Middle East conflicts' to 'Increasing tensions between countries, such as China and Taiwan, and other conflicts including the Ukraine-Russia war, the United States and Israel conflict with Iran, as well as other Middle East conflicts' (newer filing 2026-05-07)
- Changed medical X-ray tubes sales percentage from 'approximately 12% of our total revenue during the first quarter of fiscal year 2026' to 'approximately 11% of our total revenue during the first six months of fiscal year 2026' (newer filing 2026-05-07)
- Notes:
- The older filing excerpt appears truncated at the end of the customer concentration risk factor; comparison limited to complete text available
- Customer concentration metric changed from 16% (January 2, 2026 quarter-end) in older filing to 19% (April 3, 2026 quarter-end) in newer filing, reflecting different reporting periods rather than a direct textual change
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days0 buys · 1 sell ($50241) — 1 selling insider
Most recent open-market transaction: 2026-03-20. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about VREX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding VREX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 5,647,259
- Reported value $59,917,418
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
VREX had 1,235,190 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
VREX had 2.93% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 3.89 days to cover at the same settlement.
- Reported short interest (shares) 1,235,190
- Short interest (% of shares outstanding) 2.93%
- Prior settlement (shares) 1,209,036
- Reported change 2.16%
- Days to cover (reported) 3.89
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Canon (CAJ)
- Thales Group
- Siemens Healthineers (SMMNY)
- Koninklijke Philips (PHG)
- GE HealthCare (GEHC)
- Fujifilm Holdings (FUJIY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare VREX vs…
VREX ranks in…
Frequently asked questions
What does VAREX IMAGING CORP (VREX) do?
Varex Imaging Corporation is a leading designer and manufacturer of X-ray imaging components, including X-ray tubes, flat panel and photon counting detectors, linear accelerators, image software processing solutions, and stand-alone X-ray systems. The company supplies global OEMs that incorporate these components into medical diagnostic imaging, security inspection, industrial quality inspection, and industrial manufacturing applications.
What sector is VAREX IMAGING CORP (VREX) in?
VAREX IMAGING CORP (VREX) is classified in the Health Care sector. Its industry is Medical imaging components and X-ray equipment manufacturing. It trades on NASDAQ.
Who are VAREX IMAGING CORP's (VREX) competitors?
Notable peers of VAREX IMAGING CORP (VREX) include Canon, Thales Group, Siemens Healthineers, Koninklijke Philips and GE HealthCare. This peer set is informational only — not financial advice.
Is VAREX IMAGING CORP (VREX) overbought or oversold right now?
VAREX IMAGING CORP (VREX) is currently in overbought territory (its 14-day RSI is 90, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on VREX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.